Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2012 March;64(1) > Minerva Urologica e Nefrologica 2012 March;64(1):7-17

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

  BASIC UROLOGY


Minerva Urologica e Nefrologica 2012 March;64(1):7-17

language: English

Molecular signaling and the role of targeted therapies in bladder cancer

Black P. C.

Department of Urologic Sciences, University of British Columbia, Vancouver, BC, USA


PDF  


Through our growing understanding of the molecular mechanisms that drive urothelial transformation and the growth, invasion and metastasis of bladder cancer, we are able to identify an increasingly broad spectrum of molecules and pathways that are suitable for novel targeted therapies. At the same time we are armed with an increasing number of agents designed to disrupt these signaling pathways, and, as these enter the clinical arena in other cancers, the barriers to use in bladder cancer patients decline. Targeted therapy for bladder cancer, however, remains in its infancy, and no major breakthroughs have been achieved. Here we review some of the molecular targets that have been best characterized in bladder cancer, as well as some of the newer targets that appear most promising. We will review the experience up to this point in testing targeted agents against these pathways, and describe some novel agents that have yet to be tested in clinical trials but have shown significant potential in pre-clinical models.

top of page

Publication History

Cite this article as

Corresponding author e-mail

peter.black@ubc.ca